Abstracts tagged "skin fibrosis and systemic sclerosis"

Abstract Number: 806 • 2018 ACR/ARHP Annual Meeting
Estradiol Levels Are Elevated in Older Men with Diffuse Cutaneous SSc and Are Associated with Decreased Survival
DeAnna Baker Frost¹, Bethany J Wolf², Christine Peoples³, Katherine Silver⁴, Maureen Laffoon⁵, Thomas A. Medsger Jr.^3,6 and Carol A. Feghali-Bostwick⁴, ¹Medicine, Division of Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC, ²Public Health Sciences, Medical University of South Carolina, Charleston, SC, ³Department of Medicine, University of Pittsburgh, Division of Rheumatology and Clinical Immunology, Pittsburgh, PA, ⁴Department of Medicine, Medical University of South Carolina, Division of Rheumatology and Immunology, Charleston, SC, ⁵Rheumatology, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁶Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disease characterized by excessive extracellular matrix deposition (ECM), leading to dermal and internal organ fibrosis. As in other…
Abstract Number: 1715 • 2018 ACR/ARHP Annual Meeting
Safety and Efficacy of Lenabasum in an Open-Label Extension of a Phase 2 Study in Diffuse Cutaneous Systemic Sclerosis Subjects
Robert F. Spiera¹, Laura K. Hummers², Lorinda Chung³, Tracy M. Frech⁴, Robyn T. Domsic⁵, Vivien Hsu⁶, Daniel E. Furst⁷, Jessica K. Gordon¹, Maureen D. Mayes⁸, Robert W. Simms⁹, Elizabeth Lee¹⁰, Scott Constantine¹⁰ and Barbara White¹⁰, ¹Hospital for Special Surgery, New York, NY, ²Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Immunology and Rheumatology, Stanford University School of Medicine, Palo Alto, CA, ⁴Division of Rheumatology, University of Utah, Salt Lake City, UT, ⁵Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁶Rheumatology, Robert Wood Johnson Medical School, New Brunswick, NJ, ⁷Pacific Arthritis Associates, Los Angeles; University of California, Los Angeles; University of Washington, Seattle; University of Florence, Italy, Los Angeles, CA, ⁸Rheumatology, University of Texas McGovern Medical School, Houston, TX, ⁹Rheumatology, Boston University School of Medicine, Boston, MA, ¹⁰Corbus Pharmaceuticals, Inc., Norwood, MA
Background/Purpose: Lenabasum is a synthetic, non-immunosuppressive, selective cannabinoid receptor type 2 agonist that activates resolution of innate immune responses. Lenabasum had acceptable safety and tolerability,…
Abstract Number: 1718 • 2018 ACR/ARHP Annual Meeting
Skin Gene Expression Profiling Predicts Longitudinal Modified Rodnan Skin Score Change
Chase Correia¹, Mary A. Carns², Kathleen Aren², Monique Hinchcliff³ and J. Matthew Mahoney⁴, ¹Rheumatology, Northwestern Feinberg School of Medicine, Chicago, IL, ²Northwestern University, Feinberg School of Medicine Scleroderma Program, Chicago, IL, ³Rheumatology, Northwestern University, Chicago, IL, ⁴Neurological Sciences, University of Vermont College of Medicine, Burlington, VT
Background/Purpose: Systemic sclerosis (SSc) causes varying degrees of skin fibrosis with varying trajectory. Extent of skin involvement is measured by the modified Rodnan skin score…
Abstract Number: 1719 • 2018 ACR/ARHP Annual Meeting
High-Throughput Quantitative Histology in Systemic Sclerosis Skin Disease Using Computer Vision
Chase Correia¹, Seamus Mawe², Mary A. Carns³, Kathleen Aren³, Aileen Hoffman⁴, Monique Hinchcliff⁵ and J. Matthew Mahoney⁶, ¹Northwestern University, Chicago, IL, ²Department of Neurological Sciences, University of Vermont Larner College of Medicine, Burlington, VT, ³Northwestern University, Feinberg School of Medicine Scleroderma Program, Chicago, IL, ⁴Northwestern Feinberg School of Medicine, Chicago, IL, ⁵Rheumatology, Northwestern University, Chicago, IL, ⁶Neurological Sciences, University of Vermont College of Medicine, Burlington, VT
Background/Purpose: The lack of a reproducible and quantitative method to accurately assess histological skin fibrosis in patients with systemic sclerosis (SSc) has long plagued clinical…
Abstract Number: 2690 • 2018 ACR/ARHP Annual Meeting
Potential Markers of Skin Involvement in Systemic Sclerosis
Radim Becvar¹, Hana Storkanova², Barbora Sumova¹, Maja Spiritovic¹, Sabina Oreska², Ladislav Šenolt¹ and Michal Tomcik², ¹Institute of Rheumatology, Prague, Czech Republic, Prague, Czech Republic, ²Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic
Background/Purpose: Skin fibrosis is a hallmark of systemic sclerosis (SSc). There are no widely accepted biomarkers of skin involvement in this condition. Several serum or…
Abstract Number: 729 • 2017 ACR/ARHP Annual Meeting
Clinically Relevant Serum Proteins in Patients with Early Diffuse Cutaneous Systemic Sclerosis
Guoshuai Cai¹, Kelsey S. Flood², Shervin Assassi³, Elana J. Bernstein⁴, Robyn T. Domsic⁵, Jessica K. Gordon⁶, Faye Hant⁷, Elena Schiopu⁸, Virginia D. Steen⁹, Tracy M. Frech¹⁰, Dinesh Khanna¹¹, Ami A. Shah¹², Victoria K. Shanmugam¹³, Flavia V. Castelino¹⁴ and Monique Hinchcliff¹⁵, ¹Department of Molecular and Systems Biology, Geisel School of Medicine at Dartmouth, Hanover, NH, ²Internal Medicine, Northwestern Medicine, Chicago, IL, ³University of Texas McGovern Medical School, Houston, TX, ⁴Rheumatology, Columbia University, New York, NY, ⁵Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁶Rheumatology, Hospital for Special Surgery, New York, NY, ⁷Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, ⁸Internal Medicine, University of Michigan Medical System, Ann Arbor, MI, ⁹Rheumatology, MedStar Georgetown University Hospital, Washington, DC, ¹⁰Division of Rheumatology, University of Utah, Salt Lake City, UT, ¹¹Division of Rheumatology and Clinical Autoimmune Center of Excellence, University of Michigan, Ann Arbor, MI, Ann Arbor, MI, ¹²Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ¹³Rheumatology, The George Washington University, Washington, DC, ¹⁴Rheumatology, Harvard Medical School, Boston, MA, ¹⁵Rheumatology, Northwestern Medicine, Chicago, IL
Background/Purpose: The Prospective Registry of Early Systemic Sclerosis (PRESS), an 11 center US cohort study of early diffuse cutaneous systemic sclerosis (dcSSc) patients, was designed…
Abstract Number: 732 • 2017 ACR/ARHP Annual Meeting
Progression of Skin Fibrosis Is Associated with Decline in Lung Function in Patients with Diffuse Cutaneous Systemic Sclerosis: A European Scleroderma Trials and Research (EUSTAR) Analysis
Wanlong Wu¹, Suzana Jordan², Nicole Graf³, Janethe Pena⁴, John Curram⁵, Yannick Allanore⁶, Marco Matucci-Cerinic⁷, Janet E. Pope⁸, Christopher Denton⁹, Dinesh Khanna¹⁰ and Oliver Distler¹, ¹Department of Rheumatology, Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, ²Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ³Graf Biostatistics, Winterthur, Switzerland, ⁴Bayer HealthCare Pharmaceuticals Inc, Whippany, NJ, ⁵Bayer Plc, Newbury, United Kingdom, ⁶Department of Rheumatology, Cochin Hospital, Paris Descartes University, Paris, France, ⁷Dept of Medicine/Div of Rheum, University of Florence, Florence, Italy, ⁸Department of Medicine, Division of Rheumatology, University of Western Ontario, St Joseph's Health Care, London, ON, Canada, ⁹Department of Rheumatology, University College London, Royal Free Hospital, London, United Kingdom, ¹⁰Division of Rheumatology, Department of Internal Medicine, Scleroderma Program, University of Michigan, Ann Arbor, MI
Background/Purpose: Previously, we have identified short disease duration (≤15 months) and low baseline modified Rodnan skin score (mRSS) (≤22/51) as independent predictors of progressive skin…
Abstract Number: 764 • 2017 ACR/ARHP Annual Meeting
Application of a Novel Computational Approach to Identify New Targets and Pathways for Therapeutic Intervention in Scleroderma
Elma Kurtagic, Joel Pradines, Anthony Manning and Ishan Capila, Research, Momenta Pharmaceuticals, Inc., Cambridge, MA
Background/Purpose: Systemic Sclerosis (SSc) is a complex autoimmune disease with chronic progressive course and high interpatient variability. It is characterized by inflammation, vascular dysfunction and…
Abstract Number: 1018 • 2017 ACR/ARHP Annual Meeting
Comprehensive Identification of Differentially Methylated Regions Associated with Systemic Sclerosis in Dermal Fibroblasts from African-American Patients
Paula S. Ramos^1,2, Willian da Silveira³, E. Starr Hazard³, Ilia Atanelishvili⁴, Robert C. Wilson⁵, Jim C. Oates¹, Galina S. Bogatkevich⁴ and Gary Hardiman^1,2,3, ¹Department of Medicine, Medical University of South Carolina, Charleston, SC, ²Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC, ³Center for Genomic Medicine, Medical University of South Carolina, Charleston, SC, ⁴Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, SC, ⁵Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, SC
Background/Purpose: The etiology and reasons underlying the ethnic disparities in systemic sclerosis (SSc) remain unknown. African-Americans are disproportionally affected by SSc, yet dramatically underrepresented in…
Abstract Number: 1680 • 2017 ACR/ARHP Annual Meeting
Higher Baseline Monocyte Count Is Associated with More Extensive Skin Involvement and Higher Mortality in Systemic Sclerosis
Vishnu Mohan¹, Purvesh Khatri², Samuel Theodore¹, Julio Charles¹, Hau Pham¹, Deepthi Nair¹, Madeleine Scott², John D. Reveille¹, Maureen D. Mayes¹ and Shervin Assassi¹, ¹University of Texas McGovern Medical School, Houston, TX, ²Stanford University, Stanford, CA
Background/Purpose: Macrophages are the primary inflammatory cell type present in the systemic sclerosis (SSc) skin. Circulating monocytes can give rise to profibrotic inflammatory cells such…
Abstract Number: 1701 • 2017 ACR/ARHP Annual Meeting
Can Durometer Differentiate Limited Versus Diffuse Cutaneous Systemic Sclerosis?
Vivek Nagaraja¹, Amber Young¹, Veronica J. Berrocal² and Dinesh Khanna¹, ¹Department of Medicine, University of Michigan Scleroderma Program, Ann Arbor, MI, ²Department of Biostatistics- School of Public Health, University of Michigan, Ann Arbor, MI
Background/Purpose: The durometer is a handheld device that measures the hardness of a surface. It has been used to measure skin hardness in patients with…
Abstract Number: 2663 • 2017 ACR/ARHP Annual Meeting
Changes in Disability over Time, and Their Relationship with Degree of Skin Thickening, in Patients with Limited and Diffuse Cutaneous Systemic Sclerosis: A Retrospective Cohort Study
Sébastien Peytrignet¹, Joanne Manning², Elizabeth Wragg³, Tonia Moore⁴, Muditha Samaranayaka³ and Ariane L. Herrick⁵, ¹Manchester Academic Health Sciences Centre, Centre for Musculoskeletal Research, Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, ²Rheumatology Department, Salford Royal NHS Foundation Trust, Salford, United Kingdom, ³Salford Royal NHS Foundation Trust, Salford, United Kingdom, ⁴Centre for Musculoskeletal Research, University of Manchester, MAHSC, Salford Royal Hospital, Salford, United Kingdom, ⁵Centre for Musculoskeletal Research, University of Manchester, MAHSC, Salford Royal Hospital, Manchester, United Kingdom
Background/Purpose: The burden of disability of systemic sclerosis (SSc) is increasingly recognised. What is less known are the factors driving this disability and how it…
Abstract Number: 2776 • 2017 ACR/ARHP Annual Meeting
Plasmacytoid Dendritic Cells in Systemic Fibrosis: Pathogenic Role in Bleomycin-Induced Fibrosis Model and Correlation with Disease in Patients with Systemic Sclerosis
Suzanne Kafaja¹, Isela Valera², Anagha Divekar³, Rajan Saggar⁴, Dinesh Khanna⁵, Daniel E. Furst⁶ and Ram R. Singh⁷, ¹Department of Internal Medicine, University of California Los Angeles, David Geffen School of Medicine, Division of Rheumatology, Los Angeles, CA, ²Autoimmunity and Tolerance Laboratory, Division of Rheumatology, Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, ³Biolegend, Sa Diego, CA, ⁴Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁵University of Michigan, Ann Arbor, MI, ⁶David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁷Autoimmunity and Tolerance Laboratory, Department of Medicine/Rheumatology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA
Background/Purpose: Fibrosis is the end-result of most inflammatory conditions, but its pathogenesis remains unclear. Studies in patients and animal models suggest a role for T-cells…
Abstract Number: 2884 • 2017 ACR/ARHP Annual Meeting
A Phase 2 Study of Safety and Efficacy of Anabasum (JBT-101), a Cannabinoid Receptor Type 2 Agonist, in Diffuse Cutaneous Systemic Sclerosis
Robert F. Spiera¹, Laura K. Hummers², Lorinda Chung³, Tracy M. Frech⁴, Robyn T. Domsic⁵, Vivien Hsu⁶, Daniel E. Furst⁷, Jessica K. Gordon¹, Maureen D. Mayes⁸, Robert W. Simms⁹, Scott Constantine¹⁰ and Barbara White¹⁰, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Medical and Rheumatology, Johns Hopkins University, Baltimore, MD, ³Rheumatology, Stanford University Medical Center, Palo Alto, CA, ⁴Division of Rheumatology, University of Utah, Salt Lake City, UT, ⁵Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁶Rheumatology, Robert Wood Johnson University Scleroderma Program, New Brunswick, NJ, ⁷David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁸University of Texas McGovern Medical School, Houston, TX, ⁹Rheumatology, Boston University School of Medicine, Boston, MA, ¹⁰Corbus Pharmaceuticals, Inc., Norwood, MA
Background/Purpose: Systemic sclerosis (SSc) is characterized in part by chronic activation of the innate immune system with fibrosis. Anabasum is a non-immunosuppressive, synthetic, orally administered…
Abstract Number: 2018 • 2016 ACR/ARHP Annual Meeting
A Clinical Risk Prediction Model for Skin Thickness Progression in Early Diffuse Scleroderma
Robyn T. Domsic¹, Mary Lucas², Virginia D. Steen³ and Thomas A. Medsger Jr.⁴, ¹Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, ²Medicine, University of Pittsburgh Scleroderma Center, Pittsburgh, PA, ³Rheumatology, Georgetown University Medical Center, Washington, DC, ⁴Department of Medicine/Rheumatology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Systemic sclerosis (SSc) is a rapidly evolving field with multiple potential therapeutic agents under development and several active clinical trials focused on treating…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].